Hi ,

We’ve just passed 9K subscribers in our mailing list, and many will be coming to the SynBioBeta conference. You may have also noticed that the SynBioBeta podcast is back with new episodes. Tune in for conversations about the present and future of synthetic biology, learn who is doing what, and get excited about the biggest industry event - which is happening in less than two weeks!

• The Scientist Turned Biotech Empresario Who Changed How We Look At Gene Editing. Discover the incredible potential of gene editing with Dr. David Liu, the Harvard inventor of base and prime editing. Learn about his groundbreaking work and visions for the future in my latest Forbes article.

Harvard University Professor David Liu, Ph.D. Credit: Juliana Sohn.

• The Quest To Wear Nature’s True Colors: Colorifix is detoxifying the fabric dyeing process by sourcing pigments from nature. Meanwhile, they work behind the scenes to partner with major fashion brands and meet with legislators. What’s impressive is that they won’t patent their color-producing strains.

Co-founders Jim Ajioka (CSO, left) and Orr Yarkoni (CEO, right).

• Using Enzymes To Capture Carbon In The Fight Against Climate Change. Novozymes, a global producer of industrial enzymes, aims to make carbon capture and storage cheaper, greener, and more efficient by utilizing an enzyme long possessed by nature: carbonic anhydrase.

Klaus Skaalum Lassen is Head of Carbon Capture and Storage at Novozymes, who, together with Saipem, is optimizing enzyme-based carbon capture.

• The SynBioBeta Podcast: Empowering Cell & Gene Manufacturing Using Computational Solutions. Claire Aldridge talks about Form Bio, the spin-out from Colossal Laboratories & Biosciences, cell and gene therapies, why they are so difficult to manufacture, and the regulatory environment for these technologies.

Claire Aldridge, Chief Strategy Officer at Form Bio.

• Always a fun time at my annual State of SynBio check-in with my good friend Theral Timpson on Mendelspod. The discussion ran the gamut from AI to DeSci to what’s in store for SynBioBeta 2023 this year. Take a listen!

• In this episode of The Bio Report, I discuss the state of the emerging bioeconomy, how biotechnology is being embraced across industries, and the unexpected places biotechnology is already showing up.

What's new at SynBioBeta 2023:

SynBioBeta 2023: The Global Synthetic Biology Conference is just over two weeks away! We look forward to bringing together experts from around the world to discuss the latest advancements and innovations in synthetic biology. 

Other news:

• Ginkgo Bioworks Partners with Boehringer Ingelheim to develop breakthrough therapies for hard-to-treat diseases.

• A new report on Benchtop DNA Synthesis Devices: Capabilities, Biosecurity Implications, and Governance draws on more than 30 interviews with experts from benchtop DNA synthesis companies, the broader biotechnology industry, the biosecurity and bioscience research communities, and other sectors. Thank you to our sponsor NTI.

• Octarine Bio and Ginkgo Bioworks Announce Partnership to Produce Natural Colors. The companies will engineer a strain to produce violacein and its derivatives, a naturally occurring bis-indole pigment with potent bioactive properties.

• Tune in this Thursday, May 11th, 2023, to learn how you can accelerate your analysis with Ganymede Bio's new virtualization and automation data products. See how they're leveraging automated analysis and virtualization to empower you and your scientists to streamline your analytical workflows and related data management. They will also be speaking at SynBioBeta.

• SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients was published in Nature Biotechnology. SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic-resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients.

• The Mayfield Way: Partnering Early with Founders to Build a Bright Future. Mayfield has raised $955 million across two new early-stage venture capital funds: Mayfield XVII ($580 million) and Mayfield Select III ($375 million), aka Mayfield Spring.

• Conagen develops better sustainable carminic acid via fermentation. The development of the intense red pigment is environmentally friendly and an alternative to traditional carminic acid extraction methods.

• Life Sciences Company Aanika Biosciences Expands to 3K SF at Industry City. Aanika Biosciences expanded its facility from 600 to 2,500 square feet in Brooklyn’s innovative Industry City campus that covers six million square feet of mixed-use space.

• Open Call for The BioFashion Show 2023: Feature your designs on the runway at the BioFashion Show in Singapore this July.

• Evonetix Delivers First Chip-synthesized DNA to the University of Cambridge: The DNA was delivered to Dr Jenny Molloy, Co-chair of the Engineering Biology Interdisciplinary Research Centre at the University of Cambridge.
  

If you’ll be at SynBioBeta this month, I can’t wait to see you.

Regards,
John

---

John Cumbers
Founder, SynBioBeta

Who's hiring?

• Senior Scientist, Fermentation at POW.BIO, Berkeley, CA
  
• Scientist, Fermentation at POW.BIO, Berkeley, CA
  
• Synthetic Biology Strategist and Program Manager at Raytheon Technologies, Remote
  
• Lab Technician / Lab Manager at E11 Bio, Alameda, CA
  
• Research Systems Engineer at Caltech, Pasadena, CA

View in Browser »

Like our Digest? Please feel free to share with friends, family, and co-workers!

SynBioBeta, LLC
3559 Mount Diablo Boulevard #2, Lafayette, CA 94549

info@synbiobeta.com

If you no longer wish to receive our emails, you can unsubscribe here.
Modify Your Email Preferences